Streetbeat News

CRVO

CervoMed Inc.

https://www.cervomed.com

Industry

Biotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Open

12.94

Mkt cap

103M

Volume

60K

High

13.30

P/E Ratio

5.42

52-wk high

26.38

Low

12.43

Div yield

N/A

52-wk low

5.85

Jones Trading has initiated coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and set a price target of $70.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 10:38 am

Virios Therapeutics shares fell 47.6% after pricing a $1.7 million public offering. Other notable movers include MultiMetaVerse Holdings, GT Biopharma, and Faraday Future Intelligent Electric, among others.

Portfolio Pulse from Avi Kapoor

May 20, 2024 | 5:28 pm

CervoMed Inc. (NASDAQ:CRVO) has appointed William Elder as Chief Financial Officer, effective June 1, 2024. Elder will also continue his roles as General Counsel and Corporate Secretary. He succeeds William Tanner, who will remain as a consultant.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:04 pm

CervoMed (NASDAQ:CRVO) reported Q1 earnings per share (EPS) of $(0.41), missing the analyst estimate of $(0.39) by 5.13%. However, the company saw a significant improvement from the $(1.95) per share loss in the same period last year. Quarterly sales were $2.35 million, surpassing the analyst estimate of $1.35 million by 73.85%.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:14 pm

Wall Street analysts have updated their price targets and ratings for several companies, including notable changes for CervoMed, Transocean, Sealed Air, Perrigo, Simply Good Foods, Shockwave Medical, Disney, BJ's Wholesale, Douglas Dynamics, and Huntington Bancshares. These adjustments reflect analysts' latest views on these stocks, with various upgrades, downgrades, and price target changes.

Portfolio Pulse from Avi Kapoor

April 08, 2024 | 12:00 pm

Canaccord Genuity analyst Sumant Kulkarni has maintained a Buy rating on CervoMed (NASDAQ:CRVO) and increased the price target from $50 to $65.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 11:38 am

CervoMed's stock price has increased following the announcement of a private placement financing. This move is likely to provide the company with additional capital, potentially boosting its operations and growth prospects.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:48 pm

CervoMed has announced a private placement financing deal, securing an upfront $50M with the potential for an additional $99.4M through the exercise of warrants.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:35 pm

Health care stocks showed significant movement in Thursday's intraday session, with notable gainers including Yield10 Bioscience, Monogram Orthopaedics, and X4 Pharmaceuticals, among others. Losers were led by Tourmaline Bio, Apyx Medical, and Ontrak. The movements were largely influenced by recent Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 5:31 pm

CervoMed Inc. (NASDAQ:CRVO) announced positive results from the AscenD-LB Phase 2a trial of neflamapimod for dementia with Lewy bodies (DLB), showing significant reduction in plasma GFAP levels compared to placebo. The reduction in GFAP correlated with improved clinical outcomes. Additionally, data from UCL demonstrated neflamapimod's potential in improving axonal transport in a tauopathy mouse model, supporting its use in frontotemporal dementia treatment. These findings will be presented at the AD/PD™ 2024 conference.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.